Abbott receives approval for next-generation xience prime drug eluting stent in japan

Abbott, 04/10/2012

Abbott announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next–generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which uses the same drug and biocompatible polymer as the XIENCE V Everolimus Eluting Coronary Stent System, features an enhanced stent design and a delivery system designed for greater flexibility, ideal radial strength, excellent longitudinal strength and more accurate stent placement.

Print Article Summary Cat 2 CME Report